Page last updated: 2024-11-11

teroxirone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6917771
MeSH IDM0092302

Synonyms (40)

Synonym
alpha-tgt
alpha-tgi
teroxirone
nsc-296934
teroxirone (usan)
59653-73-5
D06080
nsc 296934
1,3,5-triazine-2,4,6-(1h,3h,5h)-trione, 1,3,5-tris(oxiranylmethyl)-, (alpha)-
teroxironum [inn-latin]
teroxirone [usan:inn]
teroxirona [inn-spanish]
henkel's compound
s-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tris(2,3-epoxypropyl)-, alpha-
alpha-triglycidyl isocyanurate
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tris(oxiranylmethyl)-, (1(r*),3(r*),5(s*))-(+-)-
alpha-1,3,5-tris(2,3-epoxypropyl)-s-triazine-2,4,6-(1h,3h,5h)-trione
(rs,rs,sr)-1,3,5-tris(2,3-epoxypropyl)-s-triazine-2,4,6(1h,3h,5h)-trione
alphatgi
.alpha.-triglycidyl isocyanurate
gatgi
456v4159sl ,
unii-456v4159sl
teroxirona
teroxironum
teroxirone [usan]
triglycidyl isocyanurate, .alpha.-
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tris(oxiranylmethyl)-, (1(r*),3(r*),5(s*))-(+/-)-
triglycidyl isocyanurate .alpha.-form [mi]
teroxirone [inn]
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3-bis((2r)-2-oxiranylmethyl)-5-((2s)-2-oxiranylmethyl)-, rel-
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3-bis((2r)-oxiranylmethyl)-5-((2s)-oxiranylmethyl)-
1,3-bis((2r)-2-oxiranylmethyl)-5-((2s)-2-oxiranylmethyl)-1,3,5-triazine-2,4,6(1h,3h,5h)-trione
24N3OU2YDR ,
triglycidyl isocyanurate, (r,r,s)-
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3-bis((2r)-2-oxiranylmethyl)-5-((2s)-2-oxiranylmethyl)-
240408-79-1
unii-24n3ou2ydr
1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione
DTXSID301318560

Research Excerpts

Overview

Teroxirone is a novel triepoxide, synthesized as an alkylator and showing a broad spectrum of preclinical activity.

ExcerptReferenceRelevance
"Teroxirone is a novel triepoxide, synthesized as an alkylator and showing a broad spectrum of preclinical activity. "( Phase I trial of teroxirone.
Derocher, D; Grever, MR; Kraut, EH; Malspeis, L; Neidhart, JA, 1984
)
2.05
"Teroxirone is an experimental triepoxide antitumor agent currently undergoing evaluation in clinical trials. "( Pharmacological characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans.
Ames, MM; Kovach, JS; Rubin, J, 1984
)
1.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (40.00)18.7374
1990's7 (20.00)18.2507
2000's6 (17.14)29.6817
2010's8 (22.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.08 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies14 (40.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]